FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 1998
1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the signs and symptoms of benign prostatic hyperplasia (BPH) 2. To evaluate patient\'s tolerability to the use of FLOMAX® capsules 0.4 mg daily in comparison to HYTRIN® capsules, 5 mg (with titration) daily for the treatment of the symptoms of benign prostatic hyperplasia
Epistemonikos ID: 4e4db15c38c2786e51370e79dcc59ae304c96dec
First added on: May 12, 2024